Drug Abuse Survey with Confirmation, Evaluation 1, Urine
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
This test was designed to screen for and confirm by gas chromatography-mass spectrometry (GC-MS) or gas chromatography-flame ionization detection (GC-FID) the following drugs:
This assay represents the coupling of IDOAU / Drug Abuse Survey, Urine with an automatic confirmation of all positive results by the definitive assay available and described elsewhere (eg, AMPHU / Amphetamines, Urine). All positive screening results are confirmed by GC-MS or GC-FID, and quantitated, before a positive result is reported.
Detecting drug abuse involving amphetamines, barbiturates, cocaine, ethanol, methadone, opiates, phencyclidine, and propoxyphene
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.
A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/index.html
Creatinine and specific gravity are measured as indicators of specimen dilution.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Not intended for use in employment related testing.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).
For situations where chain of custody is required, a Chain-of-Custody Kit (Supply T282) is available. See COCH / Chain-of-Custody Processing.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 30 mg/dL
Methadone: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Propoxyphene: 300 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Physicians Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006
2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006
3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188